Resources

La iniciativa Aceleración y Aprendizaje del Uso de Datos (DUAL) documentó las experiencias de cinco países africanos que digitalizaron sus sistemas de salud. Muchos países están trabajando con socios para fortalecer el uso de datos de salud y mejorar los resultados de salud mediante la digitalización de sus sistemas de atención médica. Sin embargo, las inversiones, directrices y políticas en salud digital que promueven las partes interesadas a nivel mundial no siempre reflejan las prioridades de los países o el progreso hacia la transformación digital.La innovación y las lecciones que surgen a nivel de país a menudo no se incluyen en el financiamiento, la orientación normativa y los enfoques programáticos. El objetivo de DUAL es compartir las mejores prácticas en el uso de la transformación digital para acelerar el uso de datos y mejorar los resultados de salud. Los hallazgos de la iniciativa forman la base del modelo "DUAL", que los gobiernos de los países, los encargados de formular políticas, los implementadores y los financiadores pueden utilizar para fortalecer la adopción de las tecnologías digitales. El modelo DUAL identifica diez elementos de transformación digital, agregando dos nuevos componentes a los componentes básicos de la estrategia de eSalud de la OMS y la UIT: la gestión del cambio y los ecosistemas de uso de datos. El modelo destila los factores clave de éxito para cada elemento y recomienda acciones prácticas específicas para los países.

In 2021, PATH undertook a subnational assessment in Burkina Faso, Ethiopia, India, Kenya, and Nigeria on barriers and enablers to uptake and implementation of essential maternal, newborn, and child health and nutrition medicines, devices, and interventions—what we call “assets.” We conducted facility spot-checks of asset availability and interviewed healthcare providers and district health management teams on challenges and successes in the journey to scale for each of the 14 assets. The Insights Briefs summarize the findings for each focus country.

The purpose of this action brief is to review and discuss the current situation of Hepatitis-C Virus (HCV) among People Who Inject Drugs (PWID) in India. Further, this action brief would provide potential strategies in strengthening HCV screening, confirmatory testing, treatment initiation, and treatment completion among PWIDs in India.

Diagnostics are fundamental to accurate detection of disease and critical to informing effective clinical care and selection of treatment. Yet access to diagnostic testing has remained poor and inequitable in many parts of the world. Approximately 47 percent of the global population has little to no access to diagnostics. This challenge is particularly evident in low- and middle-income countries, where only 19 percent of patients have access to appropriate diagnostics at the primary health care level.To develop this report, PATH collaborated with Accenture to investigate access challenges within the diagnostics ecosystems in Latin America, Africa, and Southeast Asia to identify market failures and market-shaping interventions needed for LMICs and close the existing diagnostics gap. The report highlights existing market failures across the diagnostics value chain and provides recommendations for expanded access to quality diagnostics in low- and middle-income countries.Click here to view an interactive dashboard of diagnostic companies with a manufacturing presence based in Africa, Latin America, and Southeast Asia.

From 2018-2022, the Devices, Diagnostics, and Drugs to AddressWomen’s Needs (D3AWN) Product Development Partnership (PDP)program advanced a portfolio of four products for the prevention andmanagement of postpartum hemorrhage (PPH) and preeclampsia/eclampsia (PE/E) in African markets: the Ellavi uterine balloontamponade (UBT), LifeAssay Test-it™ protein-to-creatinine (PrCr)Urinalysis Dipstick Test, RELI Delivery system, and oxytocin insublingual fast-dissolving tablet formulation.